Last edition
News about "Professor Jihui Hao"
HUTCHMED Begins Phase III Trial of Surufatinib-Camrelizumab Combo in Pancreatic Cancer
HUTCHMED has initiated the phase-III stage of its phase-II/III clinical trial in China evaluating a combination regimen of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, with the first patient dosed on 30 December, 2025.
Professor Jihui Hao | 05/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members